Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Basel, Switzerland

About this trial

This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of lymphedema two years after randomization.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Written informed consent according to ICH/GCP regulations prior to any trial specific procedures.

Patients ≥ 18 years of age.

Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) American Joint Committee on Cancer/ International Union Against Cancer (AJCC/UICC) stage II-III (all molecular subtypes allowed).

Node-positivity detected by imaging and non-palpable (iN+) and confirmed by pathology.

Disqualifiers

Stage IV breast cancer.

Clinical N3c breast cancer without axillary disease (clinical N3a and clinical N3b are allowed).

Clinical N2b breast cancer (clinical N2a is allowed).

Contralateral breast cancer within 3 years.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Axillary lymph node dissection (ALND)

    Procedure/Surgery

    Surgical removal of lymphatic tissue within the anatomical boundaries of the axilla (standard of care in the upfront surgery setting in patients with cN+ BC)

  • Axillary radiotherapy (ART)

    Procedure/Surgery

    Axillary irradiation

Treatment groups

1,060 Participants
are divided into 2 treatment groups
Group A: Arm A (Control): ALNDActive comparator 1 intervention
Group B: Arm B (Investigational): ARTActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in arm-related Quality of Life (QoL)

The arm subscale (ARM) of the FACT-B+4 is used to assess arm-related QoL.The FACT-B comprises five subscales: physical well-being (seven items), social well-being (seven items), emotional well-being (six items), functional well-being (seven items), and concerns specific to patients with breast cancer (13 items). The FACT-B+4 questionnaire consists of the FACT-B subscales and the additional ARM subscale including five questions related to arm morbidity with four additional validated arm morbidity items that are added to the one item on arm morbidity already included in the FACT-B questionnaire. Patients are asked to indicate on a five- point scale from 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), to 4 (very much), to what degree each statement applied over the previous 7 days. The individual scoring of each question is inverted and added up to the total score ranging between 0 and 20 points, higher scores representing less arm problems.

Time frame
From baseline to 2 years after randomization
2

Occurrence of lymphedema

Bilateral measurements will be obtained 10 cm above and 5 cm below the olecranon process on both the ipsilateral and contralateral upper extremities. The change in ipsilateral upper- extremity circumference, corrected for any change in the contralateral upper extremity, will be calculated using the following formula: L = (Ia - Ib) - (Ca- Cb). It indicates ipsilateral upper-extremity circumference, C indicates contralateral upper- extremity circumference, a indicates assessments during trial treatment and follow-up, and b indicates baseline assessment. L will be calculated for both upper arm and forearm, and lymphedema is defined as present if L \> 2 cm for either location. The proportion of patients with lymphedema will be calculated.

Time frame
From baseline to 2 years after randomization

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.